ReviewFrontiers in immunology2026
Mechanisms and therapeutic prospects of DNA methylation-mucosal innate immunity crosstalk in inflammatory bowel disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) comprises a group of chronic and relapsing intestinal inflammatory disorders whose pathogenesis and progression are closely associated with disruption of the intestinal mucosal barrier, dysregulated immune responses, and altered epigenetic regulation. The innate immune system is a central component of mucosal host defense and plays a pivotal role in pathogen recognition, inflammatory signal transduction, immune-cell functional regulation, and maintenance of barrier homeostasis. In recent years, DNA methylation has been increasingly recognized as an important mechanism contributing to the development and persistence of innate immune dysregulation in IBD by modulating the transcriptional activity of immune-related genes, inflammatory pathway genes, and barrier-function genes. Conversely, persistently activated innate immune responses may reshape DNA methylation patterns through inflammatory cytokines, oxidative stress, and signaling pathways such as NF-κB and JAK/STAT, thereby forming a dynamic bidirectional regulatory network. This review systematically summarizes the mechanisms underlying the crosstalk between DNA methylation and the innate immune system in IBD, with particular emphasis on its potential roles in inflammatory initiation, immune-cell infiltration, stabilization of pro-inflammatory phenotypes, mucosal barrier injury, inflammatory memory, and disease relapse. We further propose a conceptual framework termed the "DNA methylation-innate immunity interaction axis." Current evidence suggests that this interaction axis may provide a new mechanistic perspective for understanding the maintenance of chronic inflammation and recurrent disease activity in IBD. It may also offer a theoretical basis for combined epigenetic-immune interventions, biomarker development, and optimization of precision therapeutic strategies. Future studies integrating single-cell omics, spatial omics, longitudinal cohorts, and functional validation are warranted to further define the cell-type specificity, stage-dependent effects, and clinical translational potential of this axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.